PRESS RELEASE published on 01/23/2024 at 17:00, 1 year 10 months ago Introducing Smilefy 4.0 — Revolutionizing Dental Aesthetics With Automated 3D Smile Design Powered by AI Smilefy Inc. has announced the release of Smilefy 4.0, a cutting-edge 3D Smile Design powered by AI that is set to revolutionize cosmetic and restorative dentistry. This innovative solution enables dental professionals to create 3D Smile Designs in minutes and generate 3D print-ready mockups, shells, composite veneers, and temps models chairside, offering higher efficiency, cost savings, and a better patient experience. Integrating AI into daily dental operations, Smilefy 4.0 embodies this shift, enhancing workflow efficiency and yielding considerable time and cost savings for dental practices. With Smilefy AI automating the process of 3D smile design, the solution offers precision, adaptability, and a user-friendly platform, enhancing practice efficiency, treatment outcome accuracy, and patient satisfaction worldwide. AI Technology Smilefy 4.0 3D Smile Design Dental Aesthetics Digital Dental Solutions
Published on 12/05/2025 at 02:35, 2 hours 49 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 24 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 19 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 24 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 54 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 33 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 59 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 9 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 13 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 24 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 39 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 40 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 23 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025